Journal Article

KARAOKE: Krill oil versus placebo in the treatment of knee osteoarthritis: protocol for a randomised controlled trial

March, L., Hill, C., Jones, G., Otahal, P., Cicuttini, F. M., Wluka, A. E., Keen, H. I., Laslett, L. L., Antony, B.

2020

Overview

Background Knee osteoarthritis (OA) is a common and important cause of pain and disability, but interventions aimed at modifying structures visible on imaging have been disappointing. While OA affects the whole joint, synovitis and effusion have been recognised as having a role in the pathogenesis of OA. Krill oil reduces knee pain and systemic inflammation and could be used for targeting inflammatory mechanisms of OA. Methods/design We will recruit 260 patients with clinical knee OA, significant knee pain and effusion-synovitis present on MRI in five Australian cities (Hobart, Melbourne, Sydney, Adelaide and Perth). These patients will be randomly allocated to the two arms of the study, receiving 2 g/day krill oil or inert placebo daily for 6 months. MRI of the study knee will be performed at screening and after 6 months. Knee symptoms, function and MRI structural abnormalities will be assessed using validated methods. Safety data will be recorded. Primary outcomes are absolute change in knee pain (assessed by visual analog score) and change in size of knee effusion-synovitis over 24 weeks. Secondary outcomes include improvement in knee pain over 4, 8, 12, 16 and 20 weeks. The primary analyses will be intention-to-treat analyses of primary and secondary outcomes. Per protocol analyses adjusting for missing data and for treatment compliance will be performed as the secondary analyses. Discussion This study will provide high-quality evidence to assess whether krill oil 2 g/day reduces pain and effusion-synovitis size in older adults with clinical knee OA and knee effusion-synovitis. If krill oil is effective and confirmed to be safe, we will provide compelling evidence that krill oil improves pain and function, changes disease trajectory and slows disease progression in OA. Given the lack of approved therapies for slowing disease progression in OA, and moderate cost of krill oil, these findings will be readily translated into clinical practice. Trial registration Australian New Zealand Clinical Trials Registry, ACTRN12616000726459 . Registered on 02 June 2016. Universal Trial Number (UTN) U1111–1181-7087.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adult / Aged / Animals / Australia - epidemiology / Bioavailability / Biomedicine / Care and treatment / Cartilage / Case-Control Studies / Clinical trials / Disease Progression / Docosahexaenoic Acids - adverse effects / Docosahexaenoic Acids - economics / Docosahexaenoic Acids - therapeutic use / Double-Blind Method / Drug dosages / Euphausiacea - chemistry / Fatty acids / Female / Fish oils / Genotype & phenotype / Health Sciences / Humans / Hypotheses / Inflammation / Intention to Treat Analysis / Knee pain / Krill oil / Magnetic resonance imaging (MRI) / Magnetic Resonance Imaging - methods / Male / Medicine / Medicine & Public Health / Middle Aged / Multicenter Studies as Topic / Osteoarthritis / Osteoarthritis, Knee - diagnostic imaging / Osteoarthritis, Knee - drug therapy / Osteoarthritis, Knee - physiopathology / Pain / Pain - drug therapy / Pain Measurement - methods / Pain Measurement - statistics & numerical data / Patient compliance / Placebos - administration & dosage / Randomized Controlled Trials as Topic / Rheumatoid arthritis / Safety / Statistics for Life Sciences / Study Protocol / Synovitis - complications / Synovitis - diagnostic imaging / Synovitis - drug therapy / Treatment Outcome / Tumor necrosis factor-TNF